PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Avelumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms PICK-NEPC
- 01 Dec 2017 Planned End Date changed from 31 Oct 2022 to 31 Dec 2022.
- 01 Dec 2017 Planned primary completion date changed from 30 Apr 2020 to 30 Jun 2020.
- 01 Dec 2017 Status changed from not yet recruiting to recruiting.